+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SOTAC

Sotac Pharmaceuticals Ltd Share Price

 

 

Sotac Pharmaceuticals Ltd live price: ₹105. It opened at ₹104 vs previous close ₹105; intraday high/low: ₹105/₹104. The 50 & 200 DMA stand at ₹112.33/₹120.08.

Sotac Pharmaceuticals Ltd Performance

  • Today's Low
  • ₹104
  • Today's High
  • ₹105
  • 52 Week Low
  • ₹100
  • 52 Week High
  • ₹152
  • Open Price₹104
  • Previous Close₹105
  • Volume2,400
  • 50 DMA₹112.33
  • 100 DMA₹116.33
  • 200 DMA₹120.08

Sotac Pharmaceuticals Ltd Chart

Investment Returns

  • Over 1 Month -5.41%
  • Over 3 Month -8.7%
  • Over 6 Month -14.91%
  • Over 1 Year -24.02%

Smart Investing Starts Here Start SIP with Sotac Pharmaceuticals Ltd for Steady Growth!

Invest Now

Sotac Pharmaceuticals Ltd Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 18.4
  • PEG Ratio
  • -
  • Market Cap Cr
  • 116
  • P/B Ratio
  • 2
  • Average True Range
  • 2.75
  • EPS
  • 5.22
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -1.34
  • RSI
  • 42.5
  • MFI
  • 44.29

Latest Stock News Updates

Sotac Pharma Consolidated September 2023 Net Sales at Rs 26.67 crore, up 34.19% Y-o-Y

Sotac Pharmaceuticals Ltd Financials

Sotac Pharmaceuticals Ltd Technicals

EMA & SMA

Current Price
₹105.00
-0.45 (-0.43%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹108.80
  • 50 Day
  • ₹112.30
  • 100 Day
  • ₹116.30
  • 200 Day
  • ₹120.10

Resistance and Support

104.67 Pivot Speed
  • R3 106.33
  • R2 105.67
  • R1 105.33
  • S1 104.33
  • S2 103.67
  • S3 103.33

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sotac Pharmaceuticals Ltd has an operating revenue of Rs. 157.05 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 9% is okay, ROE of 10% is good. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 51 which is a POOR score indicating inconsistency in earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 38 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sotac Pharmaceuticals Ltd Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-26 Audited Results, Dividend & Others To consider other business matters. Final Dividend of Rs. 0.1 per equity share.
2025-11-12 Quarterly Results & Others To consider other business matters. Final Dividend of Rs. 0.1 per equity share.
2025-05-28 Audited Results, Dividend & Others To consider other business matters. Final Dividend of Rs. 0.1 per equity share.
2024-10-29 Quarterly Results
2024-08-13 Quarterly Results
Date Purpose Remarks
2025-09-19 FINAL Rs.0.00 Final Dividend of Rs. 0.1 per equity share.
View Sotac Pharmaceuticals Ltd Dividend History Arrow

Sotac Pharmaceuticals Ltd Shareholding Pattern

72.85%
16.79%
6.52%
3.84%

Sotac Pharmaceuticals Ltd FAQs

Sotac Pharmaceuticals Ltd share price is ₹105 As on 30 June, 2026 | 06:41

The Market Cap of Sotac Pharmaceuticals Ltd is ₹116 Cr As on 30 June, 2026 | 06:41

The P/E ratio of Sotac Pharmaceuticals Ltd is 18.4 As on 30 June, 2026 | 06:41

The PB ratio of Sotac Pharmaceuticals Ltd is 2 As on 30 June, 2026 | 06:41

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23